{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:43:40Z","timestamp":1786985020038,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1501,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.bbmt.2010.07.016","type":"journal-article","created":{"date-parts":[[2010,8,3]],"date-time":"2010-08-03T06:31:02Z","timestamp":1280817062000},"page":"412-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies"],"prefix":"10.1016","volume":"17","author":[{"given":"Partow","family":"Kebriaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Madden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Kazerooni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Thall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina","family":"Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borje S.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2010.07.016_bib1","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2010.07.016_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.07.016_bib3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.bmt.1704483","article-title":"Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin\u2019s lymphoma","volume":"33","author":"Popat","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.016_bib4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2010.07.016_bib5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdg008","article-title":"High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group","volume":"14","author":"Caballero","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2010.07.016_bib6","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","article-title":"BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"13","author":"Mills","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.07.016_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00277-007-0360-0","article-title":"BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin\u2019s lymphoma patients: comparative analysis of efficacy and toxicity","volume":"87","author":"Jo","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2010.07.016_bib8","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.bbmt.2009.07.014","article-title":"Busulfan and cyclophosphamide (Bu\/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience","volume":"15","author":"Ulrickson","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.016_bib9","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1080\/10428190802340184","article-title":"High-dose chemotherapy with BEAM or busulphan\/melphalan and thiotepa followed by hematopoietic cell transplantation in malignant lymphoma","volume":"49","author":"Zaucha","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.07.016_bib10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1702795","article-title":"Autologous stem cell transplantation for clinically aggressive non-Hodgkin\u2019s lymphoma: the role of preparative regimens","volume":"27","author":"Salar","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.016_bib11","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.07.016_bib12","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood.V84.7.2144.2144","article-title":"Busulfan bioavailability","volume":"84","author":"Hassan","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.07.016_bib13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/978-1-4615-1173-1_15","article-title":"Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents","volume":"112","author":"Jones","year":"2002","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.bbmt.2010.07.016_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbmt.2006.08.037","article-title":"Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule","volume":"13","author":"Madden","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.016_bib15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00043426-198921000-00017","article-title":"Central nervous system pharmacology of antileukemic drugs","volume":"11","author":"Balis","year":"1989","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bbmt.2010.07.016_bib16","first-page":"495","article-title":"A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies","volume":"18","author":"Vey","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.016_bib17","first-page":"69","article-title":"Busulphan and melphalan prior to autologous transplantation for myeloid malignancies","volume":"16","author":"Cony-Makhoul","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.016_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1365-2141.2000.01979.x","article-title":"Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma","volume":"109","author":"Lahuerta","year":"2000","journal-title":"Br\u00a0J Haematol"},{"key":"10.1016\/j.bbmt.2010.07.016_bib19","first-page":"52","article-title":"Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study","volume":"85","author":"Tribalto","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.07.016_bib20","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.bbmt.2007.08.002","article-title":"Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients","volume":"13","author":"Carreras","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.016_bib21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/bbmt.2002.v8.pm12374454","volume":"8","author":"Kashyap","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.016_bib22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.016_bib23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","article-title":"Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.016_bib24","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1080\/10428190500468584","article-title":"High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin\u2019s lymphoma","volume":"47","author":"Hosing","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.07.016_bib25","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S1083-8791(00)70064-4","article-title":"Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study","volume":"6","author":"Andersson","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.016_bib26","doi-asserted-by":"crossref","unstructured":"Kazerooni R, Madden T, McAdams P, et\u00a0al. Development and\u00a0comparison of limited sampling strategies for pharmacokinetically-guided high-dose, intravenous busulfan in BMT Tandem Meetings, 2009; Tampa, Florida.","DOI":"10.1016\/j.bbmt.2008.12.105"},{"key":"10.1016\/j.bbmt.2010.07.016_bib27","unstructured":"Dargenio DZ, Schumitzky A. ADAPT II User\u2019s Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software. Los Angeles, CA: The BMSR."},{"key":"10.1016\/j.bbmt.2010.07.016_bib28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.07.016_bib29","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.07.016_bib30","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/sim.2077","article-title":"Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments","volume":"24","author":"Thall","year":"2005","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2010.07.016_bib31","first-page":"53","article-title":"Non-parametric estimation from incomplete observations","author":"Meier","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2010.07.016_bib32","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2010.07.016_bib33","first-page":"596","article-title":"Ten-year follow-up of a single center prospective trial of unmanipulated peripheral blood stem cell autograft and interferon-alpha in early phase chronic myeloyd leukemia","volume":"86","author":"Meloni","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.07.016_bib34","doi-asserted-by":"crossref","unstructured":"Grigg AP, Stone J, Milner AD et\u00a0al. Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. Leuk Lymphoma. 51:641\u2013649.","DOI":"10.3109\/10428191003611428"},{"key":"10.1016\/j.bbmt.2010.07.016_bib35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.07.016_bib36","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.bbmt.2008.05.010","article-title":"Transplantation from matched siblings using once-daily intravenous busulfan\/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease","volume":"14","author":"Russell","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.016_bib37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-200241020-00002","article-title":"Cellular and clinical pharmacology of fludarabine","volume":"41","author":"Gandhi","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bbmt.2010.07.016_bib38","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","article-title":"Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS","volume":"14","author":"Andersson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.016_bib39","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bbmt.2008.12.489","article-title":"Busulfan in hematopoietic stem cell\u00a0transplantation","volume":"15","author":"Ciurea","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.07.016_bib40","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.leukres.2009.08.014","article-title":"5-Aza-2\u2032-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis","volume":"34","author":"Valdez","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2010.07.016_bib41","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.07.016_bib42","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/cncr.20294","article-title":"Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma","volume":"100","author":"Anagnostopoulos","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2010.07.016_bib43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.leu.2404003","article-title":"Results of a phase I\/II trial adding carmustine (300 mg\/m2) to melphalan (200 mg\/m2) in multiple myeloma patients undergoing autologous stem cell transplantation","volume":"20","author":"Comenzo","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.07.016_bib44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/10428190802630170","article-title":"Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial","volume":"50","author":"Blanes","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.07.016_bib45","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1399-0012.2006.00581.x","article-title":"High-dose busulfan and the risk of pulmonary mortality after autologous stem cell transplant","volume":"20","author":"Kalaycio","year":"2006","journal-title":"Clin Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110003174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110003174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:38:37Z","timestamp":1761057517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879110003174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S1083879110003174"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.07.016","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}